Pure Monograph vs Allos AI
Both platforms use AI in pharma, but they sit on opposite sides of the R&D pipeline. Allos is upstream formulation science for complex generics. Pure Monograph is molecule intelligence. In most programs the two are complementary rather than substitutable.
Short answer. Allos AI solves "which formulation will work" for complex generic candidates using causal AI. Pure Monograph solves "what does the public record actually say about this molecule, and where does it end". If you are still at bench screening, look at Allos. If you need the scientific case assembled, Pure Monograph is the fit.
At a glance
| Dimension | Pure Monograph | Allos AI |
|---|---|---|
| Primary deliverable | Source-traced monographs, trial analysis, intelligence briefs | Reformulation hypotheses for complex generics via causal AI |
| Category | Molecule intelligence | Upstream formulation design |
| Regulatory output | Cited reports with gaps marked; not a submission publisher | Not a regulatory authoring tool |
| Pricing | Free: one named-molecule report. No upload. Enterprise: team workspace. | Seed-stage; not public self-serve at time of writing |
| Engagement model | Self-serve report, then ask us for a team workspace | Platform + services partnership |
| Ownership | Burrard Pharmaceutical Enterprises Ltd., Vancouver BC | Allos AI, Oxford UK ($5M seed, Dec 2025) |
When each is the right call
Pick Allos when the question is "can this drug even be formulated without a bridging study?" — particularly for complex generics with modified-release, combination, or high-potency profiles where traditional DoE screens have stalled.
Pick Pure Monograph when the question is "what does public evidence say, and where does it run out". Reformulation features that recommend a change require real uploaded datasets first.
Using both in sequence
A typical workflow: Allos identifies a viable reformulation for a complex generic candidate, the sponsor validates it at bench and pilot scale, then Pure Monograph assembles the source-traced scientific case and trial analysis around that candidate. Two tools, one pipeline.
Frequently asked questions
Is Pure Monograph the same kind of tool as Allos AI?
No. Allos is an upstream discovery and reformulation platform using causal AI. Pure Monograph is molecule intelligence. They frequently coexist in the same program.
Where is Allos AI based and what is its current stage?
Allos AI is headquartered in Oxford, UK and raised a $5 million USD seed round in December 2025. Their focus has been formulation for complex generics where conventional trial-and-error cycles fail.
Which do I start with?
If you are still selecting a molecule or formulation, start upstream with Allos. If you need the public evidence assembled for a validated candidate, start with Pure Monograph.
Can Pure Monograph replace a discovery-stage tool?
No. Reformulation produces scaffolds, risks, and first-experiment plans. Predict and Optimize routines are gated behind real uploaded bench data and do not replace causal or mechanistic discovery tooling.